DarioHealth Corp. (NASDAQ:DRIO) tinted gains of +4.07% (+0.07 points) to US$1.79. The volume of 0.06 Million shares climbed down over an trading activity of 167.27 Million shares. EPS ratio determined by looking at last 12 month figures is -1.43. Over the same time span, the stock marked US$3.64 as its best level and the lowest price reached was US$1.32. The corporation has a market cap of US$28.35 Million.
DarioHealth Corp. (NASDAQ:DRIO)’s earnings per share has been growing at a 47.4 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -371.1 percent while most common profitability ratio return on investment (ROI) was -369.7 percent. The company’s institutional ownership is monitored at 1.8 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 25.4 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 1 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.5. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Trilogy Metals Inc. (NYSE:TMQ) is worth US$170.72 Million and has recently risen 4.07% to US$1.35. The latest exchange of 0.19 Million shares is below its average trading activity of 122.67 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$1.64 while the mean 12-month price target for the shares is US$3.5.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 5.86, and a price to sales ratio of 0. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 47.79%, it carries an earnings per share ratio of -0.2.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.